Skip to main content

Demyelinating diseases

Section edited by Francesco Patti

This section covers all types of demyelinating diseases. Topics of interest include, but are not limited to, multiple sclerosis, neuroimmunology, systemic lupus, vasculitis, lymphoma, and myelitis.

Page 1 of 7

  1. Susac syndrome (SuS) is a rare condition characterized by a clinical triad of sensorineural hearing loss, branch artery occlusion and encephalopathy. This study reports an increased incidence of SuS in Israel....

    Authors: A. Wilf-Yarkoni, O. Elkayam, O. Aizenstein, Y. Oron, V. Furer, D. Zur, M. Goldstein, D. Barequet, H. Hallevi, A. Karni, Z. Habot-Wilner and K. Regev

    Citation: BMC Neurology 2020 20:332

    Content type: Research article

    Published on:

  2. Nonadherence to disease-modifying drugs (DMDs) for multiple sclerosis (MS) is associated with poorer clinical outcomes, including higher rates of relapse and disease progression, and higher medical resource us...

    Authors: Jacqueline A. Nicholas, Natalie C. Edwards, Roger A. Edwards, Anna Dellarole, Megan Grosso and Amy L. Phillips

    Citation: BMC Neurology 2020 20:281

    Content type: Research article

    Published on:

  3. Several studies have reported the association between polymorphisms in Matrix metalloproteinases (MMPs) gene family and risk of Multiple sclerosis (MS). However, the results have been inconsistent and inconclu...

    Authors: Mina Mohammadhosayni, Arezou Khosrojerdi, Keivan Lorian, Saeed Aslani, Danyal Imani, Bahman Razi, Farhad Babaie and Shahram Torkamandi

    Citation: BMC Neurology 2020 20:218

    Content type: Research article

    Published on:

  4. A high multiple sclerosis activity while on alemtuzumab is rather uncommon compared to moderate-efficacy drugs. The purpose of this case report is to present a case of a 37-year-old female patient with bronchi...

    Authors: Martin Vališ, Pavel Ryška, Simona Halúsková, Blanka Klímová and Zbyšek Pavelek

    Citation: BMC Neurology 2020 20:202

    Content type: Case report

    Published on:

  5. Stress cardiomyopathy (Takotsubo cardiomyopathy) is very rare in the central nervous system (CNS) demyelinating disorders. Although this dysfunction of the heart-brain axis has been reported in several case se...

    Authors: Sungsik An, Hyeo-il Ma, Jooyeon Song, Hong-Mi Choi and Young Eun Kim

    Citation: BMC Neurology 2020 20:201

    Content type: Case report

    Published on:

  6. The prevalence of Multiple Sclerosis (MS) has been increasing worldwide and the north–south gradient of prevalence may be disappearing in the Northern hemisphere. The few previous prevalence studies performed ...

    Authors: Mariana Branco, Ivânia Alves, Ana Martins da Silva, Joaquim Pinheiro, Maria José Sá, Inês Correia, Lívia Sousa, Eva Brandão, Carlos Veira, Bernardo Gomes and Luis Ruano

    Citation: BMC Neurology 2020 20:195

    Content type: Research article

    Published on:

  7. Cognitive impairment is common in patients with multiple sclerosis (MS). Accurate and repeatable measures of cognition have the potential to be used as markers of disease activity.

    Authors: Seyed-Mahdi Khaligh-Razavi, Maryam Sadeghi, Mahdiyeh Khanbagi, Chris Kalafatis and Seyed Massood Nabavi

    Citation: BMC Neurology 2020 20:193

    Content type: Research article

    Published on:

  8. Diverse mechanisms including infections, autoimmune inflammatory reactions, neoplasms, and degeneration are involved in the central nervous system in cases of acquired immune deficiency syndrome. In such cases...

    Authors: Mayu Ishiguro, Yuji Ueno, Yuta Ishiguro, Masashi Takanashi, Kenji Murai, Guillaume Taieb, Kensuke Daida, Akimitsu Suda, Kazumasa Yokoyama, Toshio Naito and Nobutaka Hattori

    Citation: BMC Neurology 2020 20:179

    Content type: Case report

    Published on:

  9. Neurodegeneration, rather than inflammation, plays a key role in the progressive phase of multiple sclerosis (MS). Current disease modifying treatment options for people with progressive MS (PMS) do not specif...

    Authors: A. S. Gravesteijn, H. Beckerman, B. A. de Jong, H. E. Hulst and V. de Groot

    Citation: BMC Neurology 2020 20:177

    Content type: Study protocol

    Published on:

  10. Multiple sclerosis (MS) is a chronic immune mediated disease and the progressive phase appears to have significant neurodegenerative mechanisms. The classification of the course of progressive MS (PMS) has bee...

    Authors: Ethel Ciampi, Reinaldo Uribe-San-Martin, Claudia Cárcamo, Juan Pablo Cruz, Ana Reyes, Diego Reyes, Carmen Pinto, Macarena Vásquez, Rafael A. Burgos and Juan Hancke

    Citation: BMC Neurology 2020 20:173

    Content type: Research article

    Published on:

  11. The epidemiological characteristics of multiple sclerosis (MS) have been investigated in various studies, which have revealed that the prevalence of MS varies across countries. The present study was conducted ...

    Authors: Amir Almasi-Hashiani, Mohammad Ali Sahraian and Sharareh Eskandarieh

    Citation: BMC Neurology 2020 20:169

    Content type: Research article

    Published on:

  12. Research is needed to examine differences in multiple sclerosis (MS) prevalence by race-ethnicity. The goal of this study was to quantify MS prevalence in a health care system in Northern California and examin...

    Authors: Robert J. Romanelli, Qiwen Huang, Joseph Lacy, Lobat Hashemi, Alana Wong and Alden Smith

    Citation: BMC Neurology 2020 20:163

    Content type: Research article

    Published on:

  13. Fingolimod (Gilenya®), a first-in-class sphingosine-1-phosphate receptor modulator is approved for the treatment of relapsing-remitting multiple sclerosis. Fingolimod-induced selective immunosuppression leads ...

    Authors: Tobias Wienemann, Ann-Kristin Müller, Colin MacKenzie, Carina Bielor, Vivien Weyers, Orhan Aktas, Hans-Peter Hartung and David Kremer

    Citation: BMC Neurology 2020 20:158

    Content type: Case report

    Published on:

  14. Evoked potentials (EPs) are a measure of the conductivity of the central nervous system. They are used to monitor disease progression of multiple sclerosis patients. Previous studies only extracted a few varia...

    Authors: Jan Yperman, Thijs Becker, Dirk Valkenborg, Veronica Popescu, Niels Hellings, Bart Van Wijmeersch and Liesbet M. Peeters

    Citation: BMC Neurology 2020 20:105

    Content type: Research Article

    Published on:

  15. Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to f...

    Authors: Petra Dirks, Vera Zingler, Jost Leemhuis, Heike Berthold, Stefanie Hieke-Schulz, David Wormser and Tjalf Ziemssen

    Citation: BMC Neurology 2020 20:95

    Content type: Study protocol

    Published on:

  16. Neuroprotection and promotion of remyelination represent important therapeutic gaps in multiple sclerosis (MS). Acute optic neuritis (ON) is a frequent MS manifestation. Based on the presence and properties of...

    Authors: Christian Albert, Janine Mikolajczak, Anja Liekfeld, Sophie K. Piper, Michael Scheel, Hanna G. Zimmermann, Claus Nowak, Jan Dörr, Judith Bellmann-Strobl, Claudia Chien, Alexander U. Brandt, Friedemann Paul and Olaf Hoffmann

    Citation: BMC Neurology 2020 20:75

    Content type: Research article

    Published on:

  17. Information of Previous studies on the prevalence of MS, including our study conducted 12 years ago, used to shape global prevalence map of MS. According to those results, Iran placed in medium-prevalence MS r...

    Authors: Seyed Mohammad Baghbanian, Hamed Cheraghmakani, Reza HabibiSaravi, Arash Azar and Fariba Ghasemihamedani

    Citation: BMC Neurology 2020 20:52

    Content type: Research article

    Published on:

  18. In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and c...

    Authors: Mohammed AlJumah, R. Bunyan, H. Al Otaibi, G. Al Towaijri, A. Karim, Y. Al Malik, M. Kalakatawi, S. Alrajeh, M. Al Mejally, H. Algahtani, A. Almubarak, E. Cupler, S. Alawi, S. Qureshi, S. Nahrir, A. Almalki…

    Citation: BMC Neurology 2020 20:49

    Content type: Research article

    Published on:

  19. Aerobic training has the potential to restore function, stimulate brain repair, and reduce inflammation in people with Multiple Sclerosis (MS). However, disability, fatigue, and heat sensitivity are major barr...

    Authors: Augustine J. Devasahayam, Arthur R. Chaves, Wendy O. Lasisi, Marie E. Curtis, Katie P. Wadden, Liam P. Kelly, Ryan Pretty, Alice Chen, Elizabeth M. Wallack, Caitlin J. Newell, John B. Williams, Hannah Kenny, Matthew B. Downer, Jason McCarthy, Craig S. Moore and Michelle Ploughman

    Citation: BMC Neurology 2020 20:33

    Content type: Research article

    Published on:

  20. Most patients with multiple sclerosis (MS) suffer from bladder dysfunction during the course of the disease. This study was conducted to examine the prevalence of these complications among patients with MS.

    Authors: Fatemeh Nazari, Vahid Shaygannejad, Mehrdad Mohammadi Sichani, Marjan Mansourian and Valiollah Hajhashemi

    Citation: BMC Neurology 2020 20:24

    Content type: Research article

    Published on:

  21. Occurrence of basal ganglia involvement in neuromyelitis optica spectrum disorders (NMOSD) has rarely been reported and none documented pathologically.

    Authors: Shinji Ohara, Taka-aki Miyahira, Kenya Oguchi, Yo-ichi Takei, Fumihiro Yanagimura, Izumi Kawachi, Kiyomitsu Oyanagi and Akiyoshi Kakita

    Citation: BMC Neurology 2019 19:351

    Content type: Case report

    Published on:

  22. The Symbol Digit Modalities Test (SDMT) is regarded as the cognitive test of choice for people with MS (pwMS). While deficits are linked to impaired processing speed, the mechanisms by which they arise are unc...

    Authors: Bennis Pavisian, Viral P. Patel and Anthony Feinstein

    Citation: BMC Neurology 2019 19:340

    Content type: Research article

    Published on:

  23. The association between the Vitamin D Receptor (VDR) gene polymorphism and the risk of Multiple sclerosis (MS) has been evaluated in several researches. However, the findings were inconsistent and inconclusive. T...

    Authors: Danyal Imani, Bahman Razi, Morteza Motallebnezhad and Ramazan Rezaei

    Citation: BMC Neurology 2019 19:339

    Content type: Research article

    Published on:

  24. To investigate whether the serum free thyroxine (FT4) level is a prognostic factor for the first-attack neuromyelitis optica spectrum disorders (NMOSD).

    Authors: Qianyi He, Lifeng Li, Yanfei Li, Yanhui Lu, Kaimin Wu, Ruiyi Zhang, Junfang Teng, Jie Zhao and Yanjie Jia

    Citation: BMC Neurology 2019 19:329

    Content type: Research article

    Published on:

  25. The X-linked form of Charcot-Marie-Tooth disease type 1 (CMTX1) is an inherited peripheral neuropathy that arises in patients with mutations in the gap-junction beta-1 gene (GJB1).

    Authors: Youlong Liang, Jingli Liu, Daobin Cheng, Yu Wu, Liuhong Mo and Wen Huang

    Citation: BMC Neurology 2019 19:325

    Content type: Case report

    Published on:

  26. In this study, we aimed to understand the trends in total and itemized medical expenses, especially of disease-modifying therapy (DMT), for multiple sclerosis (MS) in Japan through an analysis of health insura...

    Authors: Izumi Kawachi, Shuichi Okamoto, Mariko Sakamoto, Hiroyuki Ohta, Yusuke Nakamura, Kosuke Iwasaki, Manami Yoshida, Shinzo Hiroi and Mieko Ogino

    Citation: BMC Neurology 2019 19:324

    Content type: Research article

    Published on:

  27. The relevance of regular moderate to intense exercise for ameliorating psychomotor symptoms in persons with multiple sclerosis (pwMS) is becoming increasingly evident. Over the last two decades, emerging evide...

    Authors: Sebastian Proschinger, Niklas Joisten, Annette Rademacher, Marit L. Schlagheck, David Walzik, Alan J. Metcalfe, Max Oberste, Clemens Warnke, Wilhelm Bloch, Alexander Schenk, Jens Bansi and Philipp Zimmer

    Citation: BMC Neurology 2019 19:314

    Content type: Study protocol

    Published on:

  28. Fingolimod (Gilenya®) is approved for relapsing forms of multiple sclerosis in the USA. Owing to transient heart-rate effects when initiating fingolimod, eligible patients undergo precautionary baseline assess...

    Authors: Brandon Brown, Jamie L. Weiss, Scott Kolodny, Xiangyi Meng, Ian M. Williams and John A. Osborne

    Citation: BMC Neurology 2019 19:287

    Content type: Research article

    Published on:

    The Correction to this article has been published in BMC Neurology 2019 19:336

  29. Some studies have looked at the age at menarche and risk of Multiple Sclerosis (MS).We aimed to conduct a systematic review and meta-analysis to estimate a pooled odds ratio of developing MS by increasing age ...

    Authors: Amirreza Azimi, Sara Hanaei, Mohammad Ali Sahraian, Mehdi Mohammadifar, Sreeram V. Ramagopalan and Mahsa Ghajarzadeh

    Citation: BMC Neurology 2019 19:286

    Content type: Research article

    Published on:

  30. Progressive multifocal leukoencephalopathy (PML) is a rapidly developing demyelinating disease in the cerebral white matter and is often caused by JC polyomavirus (JCV). PML after lung transplantation is rare ...

    Authors: Kazuhiro Ishii, Fumiko Yamamoto, Shinsuke Homma, Yoshinori Okada, Kazuo Nakamichi, Masayuki Saijo and Akira Tamaoka

    Citation: BMC Neurology 2019 19:263

    Content type: Case report

    Published on:

  31. Multiple sclerosis (MS) is prevalent among working age individuals (20–60 years), leading to high burden on work productivity. Few data are available about the absenteeism and presenteeism in employed individu...

    Authors: Jacqueline A. Nicholas, Batul Electricwala, Lulu K. Lee and Kristen M. Johnson

    Citation: BMC Neurology 2019 19:258

    Content type: Research article

    Published on:

  32. Demyelinating central nervous system diseases include several disorders that multiple sclerosis (MS) is identified as the most common among them. Ocular movement disturbances are a typical presentation in MS p...

    Authors: Amirhossein Akhavan Sigari, Masoud Etemadifar and Mehri Salari

    Citation: BMC Neurology 2019 19:254

    Content type: Case report

    Published on:

  33. Progressive multifocal leukoencephalopathy (PML) is a demyelinating disorder caused by JC virus (JCV). Although detecting JCV DNA in the cerebrospinal fluid (CSF) by real-time polymerase chain reaction (PCR) i...

    Authors: Kazuo Nakamichi, Michi Kawamoto, Junko Ishii and Masayuki Saijo

    Citation: BMC Neurology 2019 19:252

    Content type: Research article

    Published on:

  34. Clinical and imaging follow-up coupled with cerebrospinal fluid (CSF) and possibly serum profiling could provide information on disease activity and disability evolution in multiple sclerosis patients.

    Authors: R. Magliozzi, D. Marastoni, S. Rossi, M. Castellaro, V. Mazziotti, M. Pitteri, A. Gajofatto, S. Monaco, M. D. Benedetti and M. Calabrese

    Citation: BMC Neurology 2019 19:231

    Content type: Case report

    Published on:

  35. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is one of the most frequent types of autoimmune encephalitis. However, the instigating mechanisms are as yet not fully ascertained. Cardinal clinical man...

    Authors: Huafang Jia, Xiaoli Xie, Faying Qi, Long Wang, Lijuan Wang and Fengyuan Che

    Citation: BMC Neurology 2019 19:215

    Content type: Case report

    Published on:

  36. Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder usually associated with specific medical conditions that cause a disturbance of the CNS homeostasis. It has seldom been repor...

    Authors: Brent G. Oxford, Nicolas K. Khattar, Shawn W. Adams, Alexandra S. Schaber and Brian J. Williams

    Citation: BMC Neurology 2019 19:214

    Content type: Case report

    Published on:

  37. The Treatment Burden Questionnaire (TBQ) is a self-reported measure of the effect of treatment workload on patient wellbeing. We sought to validate the TBQ in Spanish and use it to estimate the burden of treat...

    Authors: María Célica Ysrraelit, Marcela Paula Fiol, Fernando Vazquez Peña, Sandra Vanotti, Sergio Adrián Terrasa, Viet-Thi Tran, Victor M. Montori and Jorge Correale

    Citation: BMC Neurology 2019 19:209

    Content type: Research article

    Published on:

  38. Progressive multifocal leukoencephalopathy (PML) is a rare complication of patients treated with fingolimod.

    Authors: Tim Sinnecker, Jeffrie Hadisurya, Tilman Schneider-Hohendorf, Nicholas Schwab, Karsten Wrede, Oliver Gembruch, Ralf Gold, Kerstin Hellwig, Sara Pilgram-Pastor, Ortwin Adams, Philipp Albrecht, Hans-Peter Hartung, Orhan Aktas and Markus Kraemer

    Citation: BMC Neurology 2019 19:190

    Content type: Case report

    Published on:

  39. Interleukin 36 (IL-36) cytokines belong to the IL-1 family and play an important role in some autoimmune diseases. However, the relationship between IL-36 and neuromyelitis optica spectrum disorders (NMOSD) re...

    Authors: Chun-Sheng Yang, Qiu xia Zhang, Yu Deng, Bing jie Zhou, Lin jie Zhang, Li min Li, Yuan Qi, Jing Wang, Li Yang and Fu-Dong Shi

    Citation: BMC Neurology 2019 19:185

    Content type: Research article

    Published on:

  40. Multiple sclerosis (MS) patients often struggle with treatment decisions, in part due to the increasing number of approved disease modifying therapies, each with different characteristics, and also since physi...

    Authors: Nick Bansback, Judy A. Chiu, Robert Carruthers, Rebecca Metcalfe, Emmanuelle Lapointe, Alice Schabas, Marilyn Lenzen, Larry D. Lynd and Anthony Traboulsee

    Citation: BMC Neurology 2019 19:173

    Content type: Research article

    Published on:

  41. Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year,...

    Authors: Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli and Claudio Gobbi

    Citation: BMC Neurology 2019 19:159

    Content type: Research article

    Published on: